BIMATOPROST JNO, BIMATOPROST JUNO, BIMPROZT, BIMATOPROST JN (Juno Pharmaceuticals Pty Ltd)
Product name
BIMATOPROST JNO, BIMATOPROST JUNO, BIMPROZT, BIMATOPROST JN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
115 working days (255)
Active ingredients
bimatoprost
Registration type
New generic medicine
Indication
BIMATOPROST JNO/BIMATOPROST JUNO/BIMPROZT/BIMATOPROST JN (eye drops) is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.